The US Food and Drug Administration (FDA) has accepted Rocket Pharmaceuticals’ Biologics License Application (BLA) and granted Priority Review for RP-L201 (marnetegragene autotemcel).  Rocket Pharmaceuticals is a late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need. RP-L201 is a lentiviral vector (LV)-based investigational gene therapy for […]